This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.
HOLX Launches BustTheMyth Campaign for Breast Health Awareness
by Zacks Equity Research
Hologic enters Breast Cancer Awareness Month with the launch of the BustTheMyth campaign. This campaign is aimed at busting myths regarding breast health.
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates
by Zacks Equity Research
Dare Bioscience (DARE) delivered earnings and revenue surprises of 366.67% and 96.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis
by Zacks Equity Research
Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of -63.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
by Zacks Equity Research
Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.
New Strong Sell Stocks for December 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.